DK175816B1 - Terapeutisk middel, der specifikt kan danne et kompleks med et kappeglycoprotein fra humant immundefektvirus, og som omfatter et polypeptid - Google Patents

Terapeutisk middel, der specifikt kan danne et kompleks med et kappeglycoprotein fra humant immundefektvirus, og som omfatter et polypeptid Download PDF

Info

Publication number
DK175816B1
DK175816B1 DK198905282A DK528289A DK175816B1 DK 175816 B1 DK175816 B1 DK 175816B1 DK 198905282 A DK198905282 A DK 198905282A DK 528289 A DK528289 A DK 528289A DK 175816 B1 DK175816 B1 DK 175816B1
Authority
DK
Denmark
Prior art keywords
cells
cell
virus
human
protein
Prior art date
Application number
DK198905282A
Other languages
Danish (da)
English (en)
Other versions
DK528289A (da
DK528289D0 (da
Inventor
Paul J Maddon
Raymond W Sweet
Richard Axel
James Arthos
Original Assignee
Smithkline Beckman Corp
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp, Univ Columbia filed Critical Smithkline Beckman Corp
Publication of DK528289D0 publication Critical patent/DK528289D0/da
Publication of DK528289A publication Critical patent/DK528289A/da
Application granted granted Critical
Publication of DK175816B1 publication Critical patent/DK175816B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/821—Separation of nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK198905282A 1988-02-24 1989-10-24 Terapeutisk middel, der specifikt kan danne et kompleks med et kappeglycoprotein fra humant immundefektvirus, og som omfatter et polypeptid DK175816B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/160,348 US5110906A (en) 1986-08-21 1988-02-24 Derivatives of soluble T-4
US16034888 1988-02-24
PCT/US1989/000762 WO1989008143A1 (en) 1988-02-24 1989-02-24 Derivatives of soluble t-4
US8900762 1989-02-24

Publications (3)

Publication Number Publication Date
DK528289D0 DK528289D0 (da) 1989-10-24
DK528289A DK528289A (da) 1989-12-22
DK175816B1 true DK175816B1 (da) 2005-03-07

Family

ID=22576514

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198905282A DK175816B1 (da) 1988-02-24 1989-10-24 Terapeutisk middel, der specifikt kan danne et kompleks med et kappeglycoprotein fra humant immundefektvirus, og som omfatter et polypeptid

Country Status (15)

Country Link
US (2) US5110906A (pt)
EP (1) EP0330227A3 (pt)
JP (1) JPH02503269A (pt)
KR (1) KR900700592A (pt)
AU (1) AU628072B2 (pt)
DE (1) DE330227T1 (pt)
DK (1) DK175816B1 (pt)
ES (1) ES2031805T1 (pt)
FI (1) FI102837B (pt)
GR (1) GR900300099T1 (pt)
HU (1) HU213019B (pt)
NZ (1) NZ228127A (pt)
PT (1) PT89838B (pt)
WO (1) WO1989008143A1 (pt)
ZA (1) ZA891456B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673896B1 (en) * 1986-08-21 2004-01-06 The Trustees Of Columbia University In The City Of New York Derivatives of soluble T-4
DE3751751T2 (de) 1986-08-21 1996-10-17 Univ Columbia Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
US5958678A (en) * 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
ZA887365B (en) * 1987-10-02 1990-05-30 Genentech Inc Adheson variants
EP0408372A1 (en) * 1989-07-13 1991-01-16 Smithkline Beecham Corporation Anti-viral therapy
EP0432693A1 (en) * 1989-12-11 1991-06-19 Sumitomo Chemical Company, Limited Liposomes cytotoxic to virus-infected cells
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
EP0491888A4 (en) * 1990-05-25 1992-09-02 Biogen, Inc. Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection
WO1992006220A1 (en) * 1990-10-05 1992-04-16 President And Fellows Of Harvard College Detection and isolation of ligands
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6274134B1 (en) 1992-01-29 2001-08-14 National Institutes Of Health Human cell adhesion protein AAMP-1 and uses thereof
US5750394A (en) * 1994-05-20 1998-05-12 The Mount Sinai Medical Center Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US6503703B1 (en) 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
CA2291483C (en) * 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6797462B1 (en) * 1998-06-23 2004-09-28 Uab Research Foundation Cell-based assay for immunodeficiency virus infectivity and sensitivity
US6586207B2 (en) * 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US7323174B1 (en) * 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
AU2002320352A1 (en) 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
AU2002363465A1 (en) * 2001-10-25 2003-05-19 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
WO2006098724A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of California Methods for treating hiv by inhibiting cd4 down-modulation
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
US8912047B2 (en) * 2011-05-18 2014-12-16 Infineon Technologies Ag Method for producing a metal layer on a substrate and device
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144983A (en) * 1981-02-27 1982-09-07 Otsuka Pharmaceut Factory Inc Preparation of physiologically active substance
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
US4663436A (en) * 1984-04-24 1987-05-05 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
DE3751751T2 (de) * 1986-08-21 1996-10-17 Univ Columbia Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV

Also Published As

Publication number Publication date
PT89838B (pt) 1994-02-28
EP0330227A3 (en) 1991-01-30
AU628072B2 (en) 1992-09-10
NZ228127A (en) 1991-11-26
ZA891456B (en) 1990-01-31
US5422274A (en) 1995-06-06
US5110906A (en) 1992-05-05
DE330227T1 (de) 1990-09-27
FI102837B1 (fi) 1999-02-26
EP0330227A2 (en) 1989-08-30
KR900700592A (ko) 1990-08-16
HU213019B (en) 1997-01-28
AU4071889A (en) 1989-09-22
DK528289A (da) 1989-12-22
ES2031805T1 (es) 1993-01-01
FI895049A0 (fi) 1989-10-24
GR900300099T1 (en) 1991-09-27
PT89838A (pt) 1989-10-04
DK528289D0 (da) 1989-10-24
JPH02503269A (ja) 1990-10-11
HUT52814A (en) 1990-08-28
WO1989008143A1 (en) 1989-09-08
FI102837B (fi) 1999-02-26

Similar Documents

Publication Publication Date Title
DK175816B1 (da) Terapeutisk middel, der specifikt kan danne et kompleks med et kappeglycoprotein fra humant immundefektvirus, og som omfatter et polypeptid
DK175520B1 (da) DNA, der koder T-celleoverfladeproteinet T4, og anvendelse af T-4 i behandlingen af AIDS
US5126433A (en) Soluble forms of the t cell surface protein cd4
Hildreth et al. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation
Camerini et al. A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site
Koenig et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
Bastiani et al. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions
EP0699077B1 (en) Hiv immunogenic complexes
US5817767A (en) Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
US5958678A (en) DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
Yanagi et al. Restricted V-segment usage in T-cell receptors from cytotoxic T lymphocytes specific for a major epitope of lymphocytic choriomeningitis virus
EP0318562A1 (en) METHOD FOR SELECTIVE INHIBITION OF HIV.
O'Brien et al. Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4
Watanabe et al. A simian immunodeficiency virus envelope V3 cytotoxic T-lymphocyte epitope in rhesus monkeys and its restricting major histocompatibility complex class I molecule Mamu-A* 02
Chen et al. Predominant use of a T-cell receptor V beta gene family in simian immunodeficiency virus Gag-specific cytotoxic T lymphocytes in a rhesus monkey
Olivetta et al. cis expression of the F12 human immunodeficiency virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication-defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails
Sattentau The role of the CD4 antigen in HIV infection and immune pathogenesis
US6673896B1 (en) Derivatives of soluble T-4
EP0313377A1 (en) Process for purification of soluble T4
Langner et al. Antiviral effects of different CD4-immunoglobulin constructs against HIV-1 and SIV: immunological characterization, pharmacokinetic data and in vivo experiments
CA1340702C (en) Derivatives of soluble t-4
NO308311B1 (no) FremgangsmÕte for fremstilling av et polypeptid som har evnen til spesifikt Õ danne et kompleks med humant immunsviktviruskappeprotein
EP0423198B1 (en) Antibodies specific towards hiv 1 gp 48

Legal Events

Date Code Title Description
PUP Patent expired